Wall street estimates Earnings report Kintara Therapeutics (NASDAQ:KTRA)

0
63

Earnings results for Kintara Therapeutics (NASDAQ:KTRA)

Kintara Therapeutics, Inc. is estimated to report earnings on 09/22/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.09. The reported EPS for the same quarter last year was $-0.89.

Analyst Opinion on Kintara Therapeutics (NASDAQ:KTRA)

1 Wall Street analysts have issued ratings and price targets for Kintara Therapeutics in the last 12 months. Their average twelve-month price target is $6.00, predicting that the stock has a possible upside of 313.79%. The high price target for KTRA is $6.00 and the low price target for KTRA is $6.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”

Kintara Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $6.00, Kintara Therapeutics has a forecasted upside of 313.8% from its current price of $1.45. Kintara Therapeutics has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: Kintara Therapeutics (NASDAQ:KTRA)

Kintara Therapeutics does not currently pay a dividend. Kintara Therapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Kintara Therapeutics (NASDAQ:KTRA)

In the past three months, Kintara Therapeutics insiders have not sold or bought any company stock. Only 5.70% of the stock of Kintara Therapeutics is held by insiders. Only 2.14% of the stock of Kintara Therapeutics is held by institutions.

Earnings and Valuation of Kintara Therapeutics (NASDAQ:KTRA

Earnings for Kintara Therapeutics are expected to grow in the coming year, from ($0.56) to ($0.34) per share. The P/E ratio of Kintara Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Kintara Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

More latest stories: here